Laboratory research use only Not for human or veterinary use U.S. researchers

  1. Home
  2. Research

Guide · The literature

No study of the blend.

There is no published study of this four-peptide pen or vial as one product. The five papers below are the seller’s own short reading list. Each one was opened. Each one is about a single component, or about thymosin beta-4 rather than the fragment named on the KLOW certificate. None of them is a study of KLOW.

The gap.

A paper about one peptide is not a paper about four peptides in a pen.

Palm Beach Vitality’s KLOW research page lists five PubMed records and no study of the filled blend.6 This page uses that list and does not add a longer review. The journal plate on each study is drawn for this page. It names the real journal and year. It is not the publisher’s cover.

Study authors are credited for their papers. They did not write, review, or endorse this site. Where a paper uses therapeutic language, that language is the authors’ statement about the single molecule they studied. This site does not adopt it as a statement about KLOW.

KPV papers.

Two papers about the Lys-Pro-Val tripeptide. Neither puts that tripeptide in a solution with BPC-157, TB-500, and GHK-Cu.

KPV · CELLS AND MICE Gastroenterology 2008 Vol. 134 · pp. 166–178 ONE PEPTIDE · NOT THE BLEND

01 · KPV · Cells and two mouse models

The tripeptide, studied on its own

G. Dalmasso, L. Charrier-Hisamuddin, H. T. T. Nguyen, Y. Yan, S. Sitaraman, and D. Merlin, 2008

A paper about KPV. Not a paper about KLOW.

1 The authors studied whether the Lys-Pro-Val tripeptide enters intestinal epithelial cells and immune cells through the PepT1 transporter, and what they observed in two mouse colitis models. They discuss KPV as a candidate in that line of research. That discussion is about KPV alone. It is not a controlled human trial, and it is not a test of this pen or vial.

Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178. PMID 18061177 doi:10.1053/j.gastro.2007.10.026

KPV · MOUSE MODEL J. Pharmacol. Exp. Ther. 2003 Vol. 306 · pp. 631–637 ONE PEPTIDE · NOT THE BLEND

02 · KPV · Compared with other MSH pieces

The C-terminal tripeptide, in mice

S. J. Getting, H. B. Schiöth, and M. Perretti, 2003

A comparison of KPV with other fragments of alpha-MSH. Not a test of the blend.

2 The authors identify KPV as the C-terminal tripeptide of alpha-melanocyte-stimulating hormone. In a mouse peritonitis model they report that KPV reduced the accumulation of neutrophils, and that this effect did not match the effect of the core melanocortin peptides. The experiment compares those fragments. It does not include BPC-157, TB-500, or GHK-Cu, and it is not a human trial of KLOW.

Getting SJ, Schiöth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. 2003;306(2):631–637. PMID 12750433 doi:10.1124/jpet.103.051623

The BPC-157 paper.

A review of animal wound models of the 15-amino-acid peptide, from the laboratory that produced much of that work.

BPC-157 · REVIEW Frontiers in Pharmacology 2021 Vol. 12 · 627533 ONE PEPTIDE · NOT THE BLEND

03 · BPC-157 · Review from Zagreb

Animal wound models of one peptide

S. Seiwerth, M. Milavic, J. Vukojevic, and colleagues, 2021

A review of BPC-157. Not a review of KLOW.

3 Seiwerth and colleagues review animal wound models of BPC-157, the synthetic 15-amino-acid peptide. The review comes from the University of Zagreb group that produced much of that literature. It discusses BPC-157 on its own. It is not a controlled human trial, and it is not a study of a solution that also contains KPV, a thymosin fragment, and GHK-Cu. This site does not carry the review’s therapeutic wording over to the blend. BPC-157’s own U.S. record is on bpc157pens.com.

Seiwerth S, Milavic M, Vukojevic J, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Front Pharmacol. 2021;12:627533. PMID 34267654 doi:10.3389/fphar.2021.627533

The GHK paper.

A review of the tripeptide and its copper complex. Not a review of the four-peptide product.

GHK AND GHK-Cu J. Biomater. Sci. Polym. Ed. 2008 Vol. 19 · pp. 969–988 ONE PEPTIDE · NOT THE BLEND

04 · GHK-Cu · Review

The copper complex, by itself

L. Pickart, 2008

About glycyl-L-histidyl-L-lysine and GHK-Cu. Not about KLOW.

4 Pickart reviews the tripeptide GHK and the copper complex it forms, GHK-Cu. The paper summarizes laboratory observations and some human observations the author attributes to that complex, including tissue-remodeling work. Those statements are about GHK and GHK-Cu. They are not evidence about a blend that also contains KPV, BPC-157, and a thymosin fragment, and they are not a study of this pen or vial.

Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969–988. PMID 18644225 doi:10.1163/156856208784909435

The thymosin beta-4 paper.

A review of the longer peptide, thymosin beta-4. The KLOW certificate names a 17–23 fragment. This paper is not a test of that fragment in this pen.

THYMOSIN BETA-4 Expert Opin. Biol. Ther. 2012 Vol. 12 · pp. 37–51 NOT THE FRAGMENT IN THIS PEN

05 · Thymosin β4 · Review

The parent peptide, not the named fragment

A. L. Goldstein, E. Hannappel, G. Sosne, and H. K. Kleinman, 2012

About thymosin beta-4. Not about the KLOW blend, and not a test of the 17–23 fragment as sold in this pen.

5 The authors review thymosin beta-4, a longer peptide that binds actin, and they discuss proposed clinical uses of that molecule. The seller describes TB-500 on the KLOW label as a synthetic actin-binding fragment of thymosin beta-4. The pen certificate names the analyte “TB500 (17–23 Fragment).” This paper is about the longer peptide. It does not test that fragment as filled in the KLOW pen or vial, and it does not test the four-peptide solution.

Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37–51. PMID 22074294 doi:10.1517/14712598.2012.634793

Sources

The five papers are the seller’s list. The descriptions above are from the papers. The authors did not write, review, or endorse this site.

  1. Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178. PMID 18061177
  2. Getting SJ, Schiöth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. 2003;306(2):631–637. PMID 12750433
  3. Seiwerth S, Milavic M, Vukojevic J, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Front Pharmacol. 2021;12:627533. PMID 34267654
  4. Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969–988. PMID 18644225
  5. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37–51. PMID 22074294
  6. Palm Beach Vitality. KLOW research page, the five-paper reading list, checked November 18, 2026. palmbeach-vitality.store
NextFrequently asked questions